Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh bought 7,905 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were purchased at an average price of $18.25 per share, for a total transaction of $144,266.25. Following the purchase, the director owned 3,088,888 shares in the company, valued at $56,372,206. This represents a 0.26% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Behzad Aghazadeh also recently made the following trade(s):
- On Friday, July 24th, Behzad Aghazadeh purchased 2,383,333 shares of Scribe Therapeutics stock. The stock was acquired at an average price of $15.15 per share, with a total value of $36,107,494.95.
Scribe Therapeutics Stock Up 1.7%
NASDAQ:SCTX opened at $18.36 on Thursday. Scribe Therapeutics Inc. has a 52 week low of $17.31 and a 52 week high of $25.49.
Read More
- Five stocks we like better than Scribe Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
